Subra Kugathasan

Ureteropelvic junction obstruction: an overlooked cause of cyclic vomiting.

Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction.

Pancreatitis as a presenting manifestation of pediatric Crohn's disease: a report of three cases.

Dermatologic manifestations of Crohn disease in children: response to infliximab.

Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study.

Pancreatitis in children.

Inflammatory bowel disease.

Guidelines for immunizations in patients with inflammatory bowel disease.

CARD15 gene mutations and risk for early surgery in pediatric-onset Crohn's disease.

Comparative phenotypic and CARD15 mutational analysis among African American, Hispanic, and White children with Crohn's disease.

Asymptomatic inflammatory bowel disease presenting with mucocutaneous findings.

A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease.

Severe colitis in children.

Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience.

Molecular stratification of Crohn's disease by chemokine receptors: fractalkine receptor polymorphisms define a fibrostenosing ileal subgroup.

Evidence of transmission ratio distortion of DLG5 R30Q variant in general and implication of an association with Crohn disease in men.

Contribution of OCTN variants within the IBD5 locus to pediatric onset Crohn's disease.

The natural history of corticosteroid therapy for ulcerative colitis in children.

Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease.

Inflammatory bowel disease--environmental modification and genetic determinants.

Health-related quality of life in the first year after a diagnosis of pediatric inflammatory bowel disease.

Challenges in pediatric inflammatory bowel disease.

Functional genomics and its implications for molecular medicine.

What are the risk factors for surgery and their implications for management of children with Crohn's disease?

DLG5 R30Q variant is a female-specific protective factor in pediatric onset Crohn's disease.

Natalizumab therapy for moderate to severe Crohn disease in adolescents.

Intercenter variation in initial management of children with Crohn's disease.

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.

Analysis of keratin polypeptides 8 and 19 variants in inflammatory bowel disease.

Laboratory values for children with newly diagnosed inflammatory bowel disease.

Pediatric inflammatory bowel disease: clinical and molecular genetics.

Progress in basic inflammatory bowel disease research.

Pediatric onset Crohn's colitis is characterized by genotype-dependent age-related susceptibility.

Body mass index in children with newly diagnosed inflammatory bowel disease: observations from two multicenter North American inception cohorts.

Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease.

CARD15 and IL23R influences Crohn's disease susceptibility but not disease phenotype in a Brazilian population.

Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease.

Effect of early immunomodulator use in moderate to severe pediatric Crohn disease.

Increased immune reactivity predicts aggressive complicating Crohn's disease in children.

Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease.

Searching for new clues in inflammatory bowel disease: tell tales from pediatric IBD natural history studies.

Course and treatment of perianal disease in children newly diagnosed with Crohn's disease.

Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study.

Age of diagnosis influences serologic responses in children with Crohn's disease: a possible clue to etiology?

Long-term outcome of maintenance infliximab therapy in children with Crohn's disease.

Appraisal of the pediatric ulcerative colitis activity index (PUCAI).

Growth abnormalities persist in newly diagnosed children with crohn disease despite current treatment paradigms.

Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn Disease.

Established genetic risk factors do not distinguish early and later onset Crohn's disease.

Barriers to adherence among adolescents with inflammatory bowel disease.

Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH.

Brief report: development of the inflammatory bowel disease family responsibility questionnaire.

Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.

Genetic determinants of pediatric inflammatory bowel disease: is age of onset genetically determined?

Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD.

Common variants at five new loci associated with early-onset inflammatory bowel disease.

Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn's disease and murine colitis.

Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD.

Comparative genetic analysis of inflammatory bowel disease and type 1 diabetes implicates multiple loci with opposite effects.

Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response.

Inflammatory bowel disease in children: current trends.

Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity.

Factors that determine risk for surgery in pediatric patients with Crohn's disease.

Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease.

Association of linear growth impairment in pediatric Crohn's disease and a known height locus: a pilot study.

Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci.

Medical radiation exposure in children with inflammatory bowel disease estimates high cumulative doses.

Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension.

Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47.

Improved risk prediction for Crohn's disease with a multi-locus approach.

Genome-wide association identifies diverse causes of common variable immunodeficiency.

Rising incidence of inflammatory bowel disease in young children: What does the future hold?

Association of Crohn's disease, thiopurines, and primary epstein-barr virus infection with hemophagocytic lymphohistiocytosis.

Crohn's disease and genetic hitchhiking at IBD5.

Medical radiation exposure in children with inflammatory bowel disease estimates high cumulative doses.

Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis.

Contribution of higher risk genes and European admixture to Crohn's disease in African Americans.

Common NOD2 risk variants in African Americans with Crohn's disease are due exclusively to recent Caucasian admixture.

Comparison of magnetic resonance enterography with endoscopy, histopathology, and laboratory evaluation in pediatric Crohn disease.

IL-10R polymorphisms are associated with very-early-onset ulcerative colitis.

Commentaries on "Workshop report: developing a pediatric inflammatory bowel diseases network and data platform in Canada": pediatric inflammatory bowel disease networks: raising the bar.

The age of gene discovery in very early onset inflammatory bowel disease.

Markers that differentiate early from late IBD.

Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.

Vertebral osteomyelitis due to Candida parapsilosis in a child with Crohn disease while receiving anti-TNF therapy.

Circulating antibodies against bacterial wall products: are there arguments for early immunosuppression?

Challenges in IBD Research: Update on Progress and Prioritization of the CCFA's Research Agenda.

Incidence, Clinical Characteristics, and Natural History of Pediatric IBD in Wisconsin: a Population-based Epidemiological Study.

Safety, Tolerability, and Clinical Response after Fecal Transplantation in Children and Young Adults with Ulcerative Colitis.

Multidimensional Prognostic Risk Assessment Identifies Association Between IL12B Variation and Surgery in Crohn's Disease.